Alinity s Anti-HCV II - Clinical Evaluation Protocol
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Jed Gorlin, M.D.
Innovative Blood Resources
Principal Investigator - Theresa A Nester, MD
Bloodworks Northwest
Principal Investigator - Thomas S Jones, Ph.D.
QualTex Laboratories
Principal Investigator - Toby L Simon, M.D.
CSL Plasma Inc.
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Innovative Blood Resources
Saint Paul, Minnesota, United States
- Csl Plasma Inc.
Knoxville, Tennessee, United States
- Qualtex Laboratories
San Antonio, Texas, United States
- Bloodworks Northwest
Renton, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 19 Apr 2021
- Primary completion
- 21 Jun 2021
- Completion
- 5 Aug 2021
- Last update posted
- 14 Oct 2022
- Registered enrollment
- 16,388
- Registry id
- NCT04862065
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.